Trials / Completed
CompletedNCT04533048
A Clinical Study to Evaluate MW33 Injection
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW33 Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This randomized, double-blind, placebo-controlled, single-dose escalation trial will be conducted to evaluate the safety, tolerability, immunogenicity, pharmacokinetic and pharmacodynamic characteristics of a single dose of MW33 injection at different doses given to healthy subjects to provide a basis for exploration of the therapeutic and preventive effects of MW33 against neocoronavirus in human.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | MW33 injection | a recombinant fully human antibody to coronavirus |
| COMBINATION_PRODUCT | MW33 injection placebo | Placebo |
Timeline
- Start date
- 2020-08-07
- Primary completion
- 2020-11-16
- Completion
- 2020-12-02
- First posted
- 2020-08-31
- Last updated
- 2021-02-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04533048. Inclusion in this directory is not an endorsement.